13.9 USD
+0.55 (+4.12%)
ChartMill assigns a Buy % Consensus number of 83% to QNRX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 42.5. This target is 205.76% above the current price.
QNRX was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about QNRX.
In the previous month the buy percentage consensus was at a similar level.
QNRX was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-15 | Maxim Group | Maintains | Buy -> Buy |
| 2022-09-07 | Alliance Global Partners | Initiate | Buy |
| 2022-05-06 | Ladenburg Thalmann | Initiate | Buy |
| 2022-01-07 | Maxim Group | Initiate | Buy |
| 2021-12-15 | JMP Securities | Initiate | Market Outperform |
QUOIN PHARMACEUTICALS LT-ADR / QNRX FAQ
What is the average price target for QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock?
8 analysts have analysed QNRX and the average price target is 42.5 USD. This implies a price increase of 205.76% is expected in the next year compared to the current price of 13.9.
What is the consensus rating for QNRX stock?
The consensus rating for QUOIN PHARMACEUTICALS LT-ADR (QNRX) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock?
The number of analysts covering QUOIN PHARMACEUTICALS LT-ADR (QNRX) is 8.